Literature DB >> 12150155

Activating Ras mutations in patients with plasma-cell disorders: a reappraisal.

Stéphane Bezieau, Hervé Avet-Loiseau, Jean-Paul Moisan, Régis Bataille.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12150155     DOI： 10.1182/blood-2002-03-0795

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.

Authors:  Kihyun Kim; Sun-Young Kong; Mariateresa Fulciniti; Xianfeng Li; Weihua Song; Sabikun Nahar; Peter Burger; Mathew J Rumizen; Klaus Podar; Dharminder Chauhan; Teru Hideshima; Nikhil C Munshi; Paul Richardson; Ann Clark; Janet Ogden; Andreas Goutopoulos; Luca Rastelli; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Br J Haematol       Date:  2010-03-12       Impact factor: 6.998

2.  A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.

Authors:  Gordan Srkalovic; Mohamad A Hussein; Antje Hoering; Jeffrey A Zonder; Leslie L Popplewell; Harsha Trivedi; Sandy Mazzoni; Rachel Sexton; Robert Z Orlowski; Bart Barlogie
Journal:  Cancer Med       Date:  2014-06-10       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.